Payment is a benefit and why it matters for pediatric trials

Alan Wertheimer has argued persuasively that research ethics committees should be willing to count payment as a benefit when evaluating studies' risk–benefit ratios. In this paper, I begin by first recapitulating his argument and adding my own, complementary one. I then do two further things. F...

Полное описание

Сохранить в:  
Библиографические подробности
Главный автор: Steel, Robert (Автор)
Формат: Электронный ресурс Статья
Язык:Английский
Проверить наличие: HBZ Gateway
Journals Online & Print:
Загрузка...
Fernleihe:Fernleihe für die Fachinformationsdienste
Опубликовано: Wiley-Blackwell 2022
В: Bioethics
Год: 2022, Том: 36, Выпуск: 7, Страницы: 757-764
Индексация IxTheo:NCH Медицинская этика
NCJ Научная этика
Другие ключевые слова:B benefit analyses / risk
B research ethics
B children and families
Online-ссылка: Volltext (lizenzpflichtig)
Volltext (lizenzpflichtig)
Описание
Итог:Alan Wertheimer has argued persuasively that research ethics committees should be willing to count payment as a benefit when evaluating studies' risk–benefit ratios. In this paper, I begin by first recapitulating his argument and adding my own, complementary one. I then do two further things. First, I explain why the practical implications of these arguments for studies enrolling competent adults are less than fully clear. Second, I explain why the practical implication for trials enrolling children are clear and significant. I argue that we should be comfortable paying children to compensate them for undergoing research risks. I propose we do so by putting money into accounts that the child gains access to upon attaining majority.
ISSN:1467-8519
Второстепенные работы:Enthalten in: Bioethics
Persistent identifiers:DOI: 10.1111/bioe.13011